UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-07, Vol.52 (1), p.73-84

2020

Volltextzugriff (PDF)

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

The American journal of gastroenterology, 2012-12, Vol.107 (12), p.1770-1776

2012

Volltextzugriff (PDF)

Long-term summer (AD751-2008) temperature fluctuation in the French Alps based on tree-ring data

Boreas, 2011-04, Vol.40 (2), p.351-366

2011

Volltextzugriff (PDF)

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

The American journal of gastroenterology, 2002-09, Vol.97 (9), p.2357-2363

2002

Volltextzugriff (PDF)

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S337-S337

2021

Volltextzugriff (PDF)

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence

United European gastroenterology journal, 2024-06, Vol.12 (5), p.574-584

2024

Volltextzugriff (PDF)

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S322-S323

2020

Volltextzugriff (PDF)

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.205-221

2017

Volltextzugriff (PDF)

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S448-S449

2021

Volltextzugriff (PDF)

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (6), p.779-791

2021

Volltextzugriff (PDF)

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

Alimentary pharmacology & therapeutics, 2020-01, Vol.51 (1), p.129-138

2020

Volltextzugriff (PDF)

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

The American journal of gastroenterology, 2022, Vol.117 (10 Suppl.), p.S704

2022

Volltextzugriff (PDF)

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

Alimentary pharmacology & therapeutics, 2019-12, Vol.50 (11-12), p.1204-1213

2019

Volltextzugriff (PDF)

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e591-e592

2022

Volltextzugriff (PDF)

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e496-e497

2022

Volltextzugriff (PDF)

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

Alimentary pharmacology & therapeutics, 2024-07, Vol.60 (7), p.897-906

2024

Volltextzugriff (PDF)

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Alimentary pharmacology & therapeutics, 2012-12, Vol.36 (11-12), p.1040-1048

2012

Volltextzugriff (PDF)

S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

The American journal of gastroenterology, 2023-12, Vol.118 (12S), p.S2-S2

2023

Volltextzugriff (PDF)

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

Alimentary Pharmacology & Therapeutics (Suppl), 2023-03, Vol.57 (5), p.496-508

2023

Volltextzugriff (PDF)

S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S624-S625

2023

Volltextzugriff (PDF)

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S338-S338

2021

Volltextzugriff (PDF)

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S10-S10

2022

Volltextzugriff (PDF)

An Analysis of Latest Data on Sequential Use of Biologic Therapies in Patients with Inflammatory Bowel Disorder: A Systematic Literature Review: 715

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S401-S402

2018

Volltextzugriff (PDF)

S972 The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e704-e705

2022

Volltextzugriff (PDF)

806 Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn’s Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S466-S466

2019

Volltextzugriff (PDF)

1 – 25 von 130

Suche als RSS-Feed

Aktive Filter

KollektionOxford Journals 2020 Medicine

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(84)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

Long-term summer (AD751-2008) temperature fluctuation in the French Alps based on tree-ring data

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

An Analysis of Latest Data on Sequential Use of Biologic Therapies in Patients with Inflammatory Bowel Disorder: A Systematic Literature Review: 715

S972 The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

806 Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn’s Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study

Aktive Filter

Suchergebnisse filtern